Literature DB >> 24166902

Conjunctival melanomas harbor BRAF and NRAS mutations--Letter.

Jaimie L Weber1, Keiran S M Smalley, Vernon K Sondak, Geoffrey T Gibney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24166902      PMCID： PMC4666498          DOI： 10.1158/1078-0432.CCR-13-2007

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Authors:  Katherine L Nathanson; Anne-Marie Martin; Bradley Wubbenhorst; Joel Greshock; Richard Letrero; Kurt D'Andrea; Steven O'Day; Jeffrey R Infante; Gerald S Falchook; Hendrik-Tobias Arkenau; Michael Millward; Michael P Brown; Anna Pavlick; Michael A Davies; Bo Ma; Robert Gagnon; Martin Curtis; Peter F Lebowitz; Richard Kefford; Georgina V Long
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

2.  Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes.

Authors:  Sarah L Lake; Fidan Jmor; Justyna Dopierala; Azzam F G Taktak; Sarah E Coupland; Bertil E Damato
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

3.  Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma.

Authors:  Henrike Westekemper; Sara Karimi; Daniela Süsskind; Gerasimos Anastassiou; Michael Freistühler; Klaus-Peter Steuhl; Norbert Bornfeld; Kurt-Werner Schmid; Florian Grabellus
Journal:  Br J Ophthalmol       Date:  2010-10-17       Impact factor: 4.638

Review 4.  Which drug, and when, for patients with BRAF-mutant melanoma?

Authors:  Sekwon Jang; Michael B Atkins
Journal:  Lancet Oncol       Date:  2013-02       Impact factor: 41.316

5.  Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.

Authors:  Klaus G Griewank; Henrike Westekemper; Rajmohan Murali; Monika Mach; Bastian Schilling; Thomas Wiesner; Tobias Schimming; Elisabeth Livingstone; Antje Sucker; Florian Grabellus; Claudia Metz; Daniela Süsskind; Uwe Hillen; Michael R Speicher; Scott E Woodman; Klaus-Peter Steuhl; Dirk Schadendorf
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531
  5 in total
  6 in total

Review 1.  Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.

Authors:  Anastasia Gkiala; Sotiria Palioura
Journal:  Clin Ophthalmol       Date:  2020-10-09

Review 2.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

3.  Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Authors:  Martine J Jager; Robert M Verdijk; Jinfeng Cao; Renier C Heijkants; Aart G Jochemsen; Mehmet Dogrusöz; Mark J de Lange; Pieter A van der Velden; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-07-22

Review 4.  Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know.

Authors:  Kalijn Fredrike Bol; Marco Donia; Steffen Heegaard; Jens Folke Kiilgaard; Inge Marie Svane
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 5.  New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.

Authors:  Jennifer Peil; Felix Bock; Friedemann Kiefer; Rebecca Schmidt; Ludwig M Heindl; Claus Cursiefen; Simona L Schlereth
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

6.  A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.

Authors:  A Maleka; G Åström; P Byström; G J Ullenhag
Journal:  BMC Cancer       Date:  2016-08-12       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.